Healixa Inc. (EMOR) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $23.0M is the value of all shares combined. Beta 0.09: the stock has moved about 91% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerHealixa Inc. (EMOR) trades at $0.03. Healixa Inc. is a technology company specializing in healthtech and fintech solutions. Founded in 1977, it offers a digital pharmacy marketplace and tech solutions across various industries. Market cap: $23.0M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for EMOR: EMOR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EMOR against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
EMOR: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Healixa Inc. (EMOR) Healthcare & Pipeline Overview
Healixa Inc. (EMOR) leverages technology to provide innovative healthtech and fintech solutions, targeting enterprise partners in diverse sectors such as travel, pharma, and logistics, while operating a digital pharmacy marketplace.
What Is the Investment Thesis for EMOR?
Healixa Inc. presents a unique investment thesis driven by its dual focus on healthtech and fintech, allowing it to tap into multiple revenue streams. Healixa's gross margin stands at 67%, indicating efficient operational management, although it currently faces challenges with a profit margin of -134%. The ongoing digital transformation in healthcare offers Healixa opportunities for growth, particularly as enterprise partners seek innovative solutions to enhance their service offerings. However, investors should be aware of the inherent risks in the healthcare technology sector, including regulatory challenges and competition.
Based on FMP financials and quantitative analysis
EMOR Key Highlights
Market Cap of $23.0M reflects Healixa's position as a small-cap player in the healthcare technology space.
- Gross margin of 67% indicates strong operational efficiency compared to industry norms.
- Profit margin of -134% highlights current financial challenges that need addressing for future profitability.
- Beta of 0.09 suggests low volatility, indicating relative stability in stock performance.
- No dividend yield as the company reinvests earnings to support growth initiatives.
Who Are EMOR's Competitors?
EMOR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CVS CVS Health Corporation | $95.29 | -0.09% | $122B | 695-pillar |
| AMGN Amgen Inc. | $382.47 | -2.25% | $206B | 815-pillar |
| VEEV Veeva Systems Inc. | $263.67 | +1.10% | $42.8B | 905-pillar |
| ZTS Zoetis Inc. | $72.89 | -0.57% | $30.6B | 855-pillar |
| MDLZ Mondelez International, Inc. | $62.47 | +0.08% | $79.7B | 645-pillar |
| BEAT HeartBeam, Inc. | $0.42 | -0.93% | $23.1M | — |
| EUDA EUDA Health Holdings Limited | $13.12 | +0.15% | $24.5M | — |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.1M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EMOR's Key Strengths?
Strong gross margin indicating operational efficiency.
- Diverse service offerings across multiple industries.
- Established digital pharmacy marketplace enhancing market reach.
- Long history in the industry provides credibility.
What Are EMOR's Weaknesses?
Current negative profit margin indicating financial challenges.
- Limited workforce may restrict growth potential.
- Dependency on enterprise partnerships for revenue.
- Brand recognition may be lower compared to larger competitors.
What Could Drive EMOR Stock Higher?
Expansion of the digital pharmacy marketplace to include additional services and products.
- Development of technology solutions tailored for employer benefits and healthcare providers.
- Strategic partnerships with logistics companies to enhance distribution capabilities.
- Launch of new healthtech solutions aimed at improving telehealth services.
- Continued investment in technology to drive innovation and operational efficiency.
What Are the Key Risks for EMOR?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory changes impacting the healthcare technology landscape.
- Competition from larger, established players in the healthtech sector.
- Economic downturns affecting enterprise spending on healthtech solutions.
- Technological advancements requiring continuous adaptation and innovation.
What Are the Growth Opportunities for EMOR?
- Healixa's established platform positions it to capture a significant share of this expanding market, leveraging partnerships with healthcare providers and insurers to enhance service offerings.
- Growth opportunity 2: The employer benefits sector is increasingly integrating healthtech solutions to improve employee wellness programs. Healixa can capitalize on this trend by offering tailored technology solutions that enhance the efficiency and effectiveness of employer-sponsored health plans, potentially increasing its client base significantly over the next three years.
- Growth opportunity 3: The logistics sector is undergoing a digital transformation, with a focus on improving supply chain efficiency in healthcare. Healixa's technology solutions can streamline logistics for pharmaceuticals, positioning the company to benefit from the increasing demand for efficient distribution channels in the healthcare supply chain.
- Growth opportunity 4: Partnerships with travel companies to provide healthtech solutions for travelers can enhance Healixa's market presence. As travel resumes post-pandemic, the demand for integrated health services during travel is expected to rise, creating new revenue streams for Healixa over the next two years.
- Growth opportunity 5: The expansion of telehealth services presents a significant opportunity for Healixa, as healthcare providers seek technology solutions to facilitate remote consultations. By developing and enhancing its digital platforms, Healixa can tap into the growing telehealth market, projected to reach $250 billion by 2028.
What Are EMOR's Competitive Advantages?
- Strong gross margin of 67% indicates operational efficiency.
- Established digital pharmacy marketplace enhances competitive positioning.
- Diverse range of services across multiple industries reduces dependency on a single market.
- Innovative technology solutions tailored to specific industry needs.
- Long-standing presence in the market since 1977 builds credibility and trust.
What Does EMOR Do?
Healixa Inc., founded in 1977 and headquartered in Holbrook, New York, operates at the intersection of healthtech and fintech. Originally established as Emerald Organic Products Inc., the company rebranded to Healixa Inc. in April 2021 to better reflect its focus on technology solutions in healthcare. With a workforce of 15 employees, Healixa has carved a niche in providing technology solutions to enterprise partner channels across various industries, including employer benefits, travel, pharmaceuticals, and logistics. The company's innovative approach includes a digital pharmacy marketplace that enhances accessibility to medications and health services. Healixa's commitment to integrating technology into healthcare aims to streamline processes and improve outcomes for its partners. As the healthcare landscape evolves, Healixa positions itself as a forward-thinking player, leveraging its expertise to address the complex demands of modern healthcare and financial services.
What Products and Services Does EMOR Offer?
- Develops technology solutions for healthtech and fintech sectors.
- Operates a digital pharmacy marketplace to enhance medication accessibility.
- Provides tech solutions to enterprise partners across various industries.
- Focuses on employer benefits, travel, pharmaceuticals, and logistics.
- Aims to streamline healthcare processes through innovative technology.
- Enhances service offerings for partners with tailored technology solutions.
How Does EMOR Make Money?
- Generates revenue through technology solutions provided to enterprise partners.
- Monetizes the digital pharmacy marketplace by facilitating transactions.
- Offers consulting services to improve operational efficiency for clients.
- Engages in partnerships with healthcare providers and insurers.
- Explores new revenue streams through innovative healthtech solutions.
What Industry Does EMOR Operate In?
The healthcare information services industry is experiencing rapid growth, driven by the increasing demand for digital health solutions and the integration of technology into traditional healthcare practices. The market is projected to expand significantly, with a compound annual growth rate (CAGR) of 25% expected over the next five years. Healixa Inc. fits into this landscape by providing innovative technology solutions that cater to various sectors, including pharmaceuticals and logistics. As competition intensifies, companies like Healixa that offer unique digital solutions are well-positioned to capture market share and drive future growth.
Who Are EMOR's Key Customers?
- Healthcare providers seeking technology solutions.
- Insurance companies looking to enhance service offerings.
- Employers aiming to improve employee health benefits.
- Travel companies needing integrated health services.
- Logistics firms requiring efficient pharmaceutical distribution.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 53 |
| 2026-08-26 | 53 |
| 2026-08-29 | 53 |
| 2026-09-01 | 53 |
| 2026-09-04 | 53 |
| 2026-09-07 | 53 |
| 2026-09-10 | 53 |
What changed?
The score has stayed at 53.
Over the same 18 days the stock moved -25.0%.
Healixa Inc. (EMOR) Valuation Context
Valued at $23.0M, EMOR is classified as a micro-cap stock.
EMOR Revenue & Earnings Trend
In Q1 FY2026, EMOR generated $0 in top-line revenue. The company recorded a net loss of $303K, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, EMOR averaged $-0.00 in diluted EPS.
Company Profile
Healixa Inc. operates in the Software - Application industry within the Technology sector. It is headquartered in Holbrook, US. The company is led by CEO Bret Hedges. EMOR has traded publicly since 2010.
Key Financial Metrics
Return on equity for Healixa Inc. stands at 9.0%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -0.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -2.8%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Healixa Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
EMOR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong gross margin indicating operational efficiency.
- Diverse service offerings across multiple industries.
- Established digital pharmacy marketplace enhancing market reach.
- Long history in the industry provides credibility.
Bear Case
- Current negative profit margin indicating financial challenges.
- Limited workforce may restrict growth potential.
- Dependency on enterprise partnerships for revenue.
- Brand recognition may be lower compared to larger competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 FY2026 | $0 | -$303,043 | -$0.0004 |
| Q3 FY2025 | $0 | -$225,080 | -$0.0003 |
| Q2 FY2025 | $0 | -$230,703 | -$0.0003 |
| Q1 FY2025 | $388,983 | -$51,226 | -$0.0001 |
Q1 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis
EMOR Latest News
-
The end of the ‘win-win’ era
International homepage · Sep 10, 2026
-
Washington Post Reported President Trump Expected To Announce A Medicare Pilot Program To Reimburse Patients' CBD Treatments
benzinga · Dec 18, 2025
-
'Trump to sign executive order reclassifying marijuana: Officials' -ABC Report
benzinga · Dec 17, 2025
-
Hess Midstream Signs $100M Repurchase That Includes Class B Units Of Hess Midstream Operations From chevron Affiliate And Hess Midstream's Class A Shares From Public
benzinga · Aug 5, 2025
EMOR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for EMOR.
Price Targets
Wall Street price target analysis for EMOR.
EMOR MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for EMOR; grades run from A+ (80-100) to F (below 30).
Latest News
The end of the ‘win-win’ era
Washington Post Reported President Trump Expected To Announce A Medicare Pilot Program To Reimburse Patients' CBD Treatments
'Trump to sign executive order reclassifying marijuana: Officials' -ABC Report
Hess Midstream Signs $100M Repurchase That Includes Class B Units Of Hess Midstream Operations From chevron Affiliate And Hess Midstream's Class A Shares From Public
Leadership: Ian Parker
CEO
Ian Parker has been leading Healixa Inc. since its rebranding in 2021, bringing extensive experience in technology and business management. He has a strong background in healthtech and fintech, having worked in various leadership roles across the technology sector. Ian holds a degree in Business Administration and has a proven track record of driving growth in technology companies.
Track Record: Under Ian's leadership, Healixa has successfully transitioned from Emerald Organic Products Inc. to a technology-focused company, expanding its service offerings and establishing a digital pharmacy marketplace. His strategic vision has positioned Healixa to capitalize on emerging trends in healthtech and fintech.
EMOR OTC Market Information
Healixa Inc. trades on the OTC Other tier, which generally includes companies that do not meet the listing requirements of major exchanges like NYSE or NASDAQ. This tier often has less stringent reporting requirements, leading to lower visibility and liquidity compared to higher tiers.
- OTC Tier: OTC Other
- Lower visibility and credibility compared to companies listed on major exchanges.
- Potential for limited liquidity affecting trading ease.
- Regulatory scrutiny may differ from that of larger exchanges.
- Higher volatility due to lower trading volumes.
- Review Healixa's latest financial statements and disclosures.
- Assess the company's market position and competitive landscape.
- Evaluate the management team's track record and experience.
- Investigate any pending regulatory issues or legal challenges.
- Consider the overall market conditions affecting the healthcare sector.
- Established presence in the market since 1977.
- Rebranding to Healixa reflects a strategic pivot towards technology.
- Partnerships with enterprise clients across various industries.
- Positive gross margin indicating operational efficiency.
What Investors Ask About Healixa Inc. (EMOR) — Healthcare
Is EMOR a good stock?
Stock Expert AI does not rate EMOR buy, sell or hold. Healixa Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about EMOR stock?
Analyst consensus on EMOR stock is limited due to its OTC status. However, key valuation metrics indicate a focus on growth potential in the healthtech sector, particularly as demand for digital solutions increases.
What are the key factors to evaluate for EMOR?
Evaluate EMOR on fundamentals, analyst consensus, and risk factors. Healixa Inc. presents a unique investment thesis driven by its dual focus on healthtech and fintech, allowing it to tap into multiple revenue streams. Not financial advice.
How frequently does EMOR data refresh on this page?
EMOR's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven EMOR's recent stock price performance?
Healixa Inc. (EMOR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong gross margin indicating operational efficiency. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EMOR overvalued or undervalued right now?
Healixa Inc. (EMOR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of EMOR?
Yes, most major brokerages offer fractional shares of Healixa Inc. (EMOR) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track EMOR's earnings and financial reports?
Healixa Inc. (EMOR) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for EMOR earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information and may be subject to change.